What role does CYP1A2 play in weight loss?

CYP1A2 primarily metabolizes caffeine. The rs762551 variant (C/*1A vs A/*1F) classifies individuals as fast or slow caffeine metabolizers. Some observational studies suggest that fast metabolizers may experience greater thermogenic and fat-oxidation benefits from caffeine, potentially aiding weight loss. Slow metabolizers, however, may have prolonged caffeine exposure, increasing risks of elevated blood pressure and sleep disruption, which could hinder weight management. The evidence for a direct causal role of CYP1A2 in weight loss is limited and mixed; most findings come from small studies or secondary analyses. No robust RCT demonstrates that tailoring caffeine intake based on CYP1A2 genotype leads to superior weight loss outcomes. Therefore, while CYP1A2 genotyping offers a plausible mechanistic link, it should not be used as a standalone weight-loss guide. Diet, exercise, and overall energy balance remain far more impactful. Caveat: consumer DNA tests lack clinical validation for weight-loss claims.